Brodalumab

Drug Profile

Brodalumab

Alternative Names: AMG-827; IL-17R mAb; KHK-4827; Kyntheum; LUMICEF; Siliq

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Kyowa Hakko Kirin; Valeant Pharmaceuticals International
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Spondylarthritis
  • Discontinued Asthma; Crohn's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 23 Jun 2017 Kyowa Hakko Kirin plans a clinical trial for Plaque psoriasis in Japan (UMIN000027783)
  • 19 May 2017 The Committee for Medicinal Products for Human Use recommends approval of brodalumab for Plaque psoriasis in European Union (SC)
  • 16 Feb 2017 Label for Brodalumab in USA carries black box warning regarding risks in patients with history of suicidal thoughts or behaviour
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top